AstraZeneca-Merck's Lynparza gets U.S. FDA nod for prostate cancer treatment

The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck & Co Inc's Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday.